{
    "clinical_study": {
        "@rank": "111220", 
        "brief_summary": {
            "textblock": "This study will measure the effectiveness and any side effects of LY317615 in patients with\n      Diffuse large B-cell lymphoma (a sub-type of Non-Hodgkins Lymphoma)."
        }, 
        "brief_title": "A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.", 
        "completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A diagnosis of recurrent or refractory Diffuse B-cell Non-Hodgkin's lymphoma.\n\n          -  Adequate organ functions.\n\n          -  Able to swallow capsules.\n\n        Exclusion Criteria:\n\n          -  More than 3 prior treatments for this disease.\n\n          -  Serious heart problems."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00054080", 
            "nct_id": "NCT00042666", 
            "org_study_id": "4849", 
            "secondary_id": "H6Q-MC-JCAI"
        }, 
        "intervention": {
            "description": "500 mg, oral, daily, up to six 28 day cycles", 
            "intervention_name": "LY317615", 
            "intervention_type": "Drug", 
            "other_name": "enzastaurin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 16, 2009", 
        "link": {
            "description": "Lilly Clinical Trial Registry", 
            "url": "http://www.lillytrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Royal Oak", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Estimate the clinical response rate in patients with relapsed or refractory DLBCL who have received LY317615", 
            "safety_issue": "No", 
            "time_frame": "baseline to measured progressive disease"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042666"
        }, 
        "responsible_party": {
            "name_title": "Chief Medical Officer", 
            "organization": "Eli Lilly"
        }, 
        "secondary_outcome": [
            {
                "measure": "Estimate objective response rate", 
                "safety_issue": "No", 
                "time_frame": "baseline to measured progressive disease"
            }, 
            {
                "measure": "Measure progression free survival", 
                "safety_issue": "No", 
                "time_frame": "baseline to measured progressive disease"
            }, 
            {
                "measure": "Duration of overall response", 
                "safety_issue": "No", 
                "time_frame": "time of response to progressive disease"
            }, 
            {
                "measure": "Evaluate safety of LY317615 in this population", 
                "safety_issue": "Yes", 
                "time_frame": "every cycle"
            }, 
            {
                "measure": "Evaluate population pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "cycle 1, day 1 and 28"
            }, 
            {
                "measure": "Assess PKC beta expression by immunohistochemistry in readily assessable DLBCL tumors from patients", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {
        "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.": "44.022 -92.47"
    }
}